Immune Design Corp. (NASDAQ:IMDZ) Director Franklin M. Berger acquired 25,000 shares of the stock in a transaction dated Monday, October 30th. The shares were bought at an average cost of $4.58 per share, with a total value of $114,500.00. Following the completion of the purchase, the director now directly owns 75,000 shares in the company, valued at $343,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Immune Design Corp. (NASDAQ:IMDZ) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%.

ILLEGAL ACTIVITY WARNING: “Immune Design Corp. (IMDZ) Director Purchases $114,500.00 in Stock” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/01/immune-design-corp-imdz-director-purchases-114500-00-in-stock.html.

A number of analysts recently weighed in on the stock. ValuEngine raised shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Royal Bank Of Canada assumed coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price target for the company. Zacks Investment Research raised shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Tuesday, July 18th. Finally, Wells Fargo & Company cut shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $29.00 to $10.00 in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $14.75.

A number of large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its stake in Immune Design Corp. by 9.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 1,600 shares during the last quarter. FMR LLC grew its position in Immune Design Corp. by 0.4% in the 1st quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock worth $3,027,000 after purchasing an additional 1,699 shares during the last quarter. California State Teachers Retirement System grew its position in Immune Design Corp. by 8.3% in the 2nd quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 2,300 shares during the last quarter. Trexquant Investment LP grew its position in Immune Design Corp. by 15.5% in the 2nd quarter. Trexquant Investment LP now owns 31,152 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 4,174 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in Immune Design Corp. by 23.0% in the 2nd quarter. Teachers Advisors LLC now owns 27,691 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 5,181 shares during the last quarter. Institutional investors and hedge funds own 51.44% of the company’s stock.

About Immune Design Corp.

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.